NASDAQ$NUWE

Nuwellis Inc · Q1 2024 earnings

Q1 2024 earnings · · Investor relations

Briefing

Nuwellis reported a revenue increase of 2% driven by consumables sales growth and gross margin improvement in Q1 2024.

Nuwellis, Inc. reported a 2% increase in revenue for the first quarter of 2024, driven by an 11% increase in consumable sales. The company's gross margin improved to 64.1% compared to 58.4% in the prior year period. Operating loss decreased due to cost-saving measures.

  • Revenue increased by 2% year-over-year to $1.9 million.
  • Consumables sales grew by 11% year-over-year, representing 82% of total revenue.
  • Pediatric revenue increased by 40% year-over-year, with consumable sales up by 54%.
  • Gross margin improved to 64.1% from 58.4% in the prior year period.

Headline financials

Total Revenue

$1.86M

Previous: $1.83M+1.7%
EPS

-$0.60

Previous: -$201.60+99.7%
Gross Margin

64.1%

Previous: 58.4%+9.8%
Capital Expenditures

-$29K

Previous: -$13K-123.1%
Free Cash Flow

-$4.36M

Previous: -$6.5M+32.9%
Net Income

-$4.33M

Previous: -$6.49M+33.2%
Operating Income

-$4.75M

Previous: -$5.85M+18.8%
Gross Profit

$1.19M

Previous: $1.07M+11.6%
R&D Expense

$1.33M

No prior period
Stock-Based Comp

$158K

Previous: $181K-12.7%

Revenue & EPS history

Nuwellis · Revenue · Quarterly

$1.86M

Q1 2024+1.7%vs Q1 2023
Beat estimate in 4 of 14 quarters(29%)
ActualEstimate

Forward guidance

Nuwellis anticipates significant expense reductions and continued positive momentum and growth in 2024.

Tailwinds

  • Expects significant expense reductions through efficiency initiatives.
  • New 12 cm catheter will provide increased access optionality and a new source of revenue.
  • Advancing pilot phase with DaVita.
  • Begin to commercialize Quelimmune™ SCD under exclusive license and distribution agreement with SeaStar Medical.
  • Increased awareness of the clinical and economic benefits of the Aquadex system continues to result in healthy utilization gains demonstrating increased therapy adoption

Headwinds

  • Risks associated with ability to execute on commercialization strategy.
  • Possibility of being unable to raise sufficient funds for anticipated operations.
  • Risks related to post-market clinical data collection activities.
  • Uncertainties regarding market and physician acceptance of products.
  • Potential risks from competitive product offerings.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 19 quarterly earnings reports · overlaid with Q1 2024

Historical avgQ1 2024

-5.5%

Avg return

Earnings day

-10.5%

Avg return

5 days after

-18.5%

Avg return

30 days after

28%

15 / 54 earnings

Positive

+51.9%

Q1 2024

Best reaction

-29.9%

Q1 2023

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-2.0%-5.0%-86.3%
Q4 2025+2.4%-2.3%-16.3%
Q3 2025-3.4%-11.9%-18.0%
Q2 2025+0.4%+8.4%-24.0%
Q1 2025-3.1%-5.1%-68.7%
Q4 2024-4.0%-7.9%-25.4%
Q3 2024+6.6%-0.6%-28.2%
Q2 2024-14.3%-30.2%-46.4%
Q1 2024+51.9%+47.1%+29.4%
Q4 2023-20.7%-18.3%-36.7%
Q3 2023-10.0%-12.9%-14.3%
Q2 2023-5.1%-3.0%-22.2%
Q1 2023-29.9%-37.8%-34.6%
Q4 2022-5.1%-6.5%-41.2%
Q3 2022-19.6%-16.7%-50.0%
Q2 2022-6.5%-4.2%+23.9%
Q1 2022+1.0%+2.9%-7.4%
Q4 2021-1.2%-6.1%+2.0%
Q3 2021-17.0%-13.2%-33.3%
Q2 2021+9.6%+7.9%+3.0%
Q1 2021-14.6%-8.9%+6.6%
Q4 2020+5.7%-6.2%-21.3%
Q3 2020-7.8%-7.0%+14.1%
Q2 2020-16.0%-32.0%-68.0%
Q1 2020-9.6%-14.6%+2.4%
Q4 2019-28.8%-33.9%-29.0%
Q3 2019-15.0%-23.0%-16.0%
Q2 2019-1.2%+2.0%+0.4%
Q1 2019-13.3%-13.3%-24.9%
Q4 2018-12.6%-25.6%-69.8%
Q3 2018+2.8%+4.7%-21.7%
Q2 2018-26.4%-37.4%-23.9%
Q1 2018-17.1%-18.8%-23.3%
Q4 2017-15.5%-25.7%-21.0%
Q3 2017-12.8%-15.6%-47.3%
Q2 2017-4.0%-13.3%-6.7%
Q1 2017-9.5%-1.4%-9.5%
Q4 2016-5.3%-12.0%-58.0%
Q3 2016-5.0%-5.0%+190.0%
Q2 2016-14.9%-16.0%-17.0%
Q1 2016+1.5%
Q4 2015-15.9%
Q3 2015-1.2%
Q2 2015+0.7%
Q1 2015-3.5%
Q4 2014-0.2%
Q3 2014-17.5%
Q2 2014+23.9%
Q1 2014+3.2%
Q4 2013+2.1%
Q1 2013+6.2%
Q4 2012+2.6%
Q2 2012-7.6%
Q4 2011+0.0%
Q3 2011

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro